Olivia Vizier

Abpro Corp., a biotechnology company developing next generation antibody therapies for severe disease, is targeting a more robust antibody response with its therapeutic, ABP 300, which is based on neutralizing monoclonal antibodies.

While an adverse event in the high-dose cohort continues to outline the limits oh high volume AAV dosing…

About a year ago, Life Science Leader Chief Editor Rob Wright posed questions to several biopharma leaders for a column in the 2019 iteration of this annual Outlook issue. At least two of those questions, had they been asked just a month or so later, would have surely yielded very different responses than they did in December

Enter GigaGen’s Surge platform, which uses single-cell sequencing to “capture and recreate” libraries of antibodies from blood donors.

Last week, privately-owned Cerevance released data from a Phase Ib biomarker study of its oral compound, CVN058, evaluating the potential of the medication as a treatment for cognitive impairment associated with schizophrenia (CIAS).

“RNA interference is often better than antibodies because of the catalytic process that you can generally use,” said Chris Anzalone, CEO of Arrowhead Pharmaceuticals. A drug like inclisiran can cut LDL cholesterol in half with only two injections per year, whereas Praluent and Repatha injections are given every 2 to 4 weeks.

Invasive fungal infections are becoming increasingly common and often pose a serious public health threat, claiming the lives of more than 1.5 million people worldwide each year.

Clene Nanomedicine is trying to set a new “gold standard” in neurodegenerative diseases through the development of a new class of drugs called bioenergetic nanotherapeutics that harnesses the properties of gold nanocrystals.

“We are fortunate to collaborate with CalciMedica, a pharmaceutical company who specializes in developing drugs suppressing calcium overload in the immune cells,” Tvrdik said. “We share the vison that our research might help to identify an effective drug that will improve the recovery of stroke survivors.”

Vaxart, a San Francisco-based biotechnology company, is testing a tablet-form Covid-19 vaccine to tackle storage temperature problems, which affect even rich countries like the US, said founder Sean Tucker. “If it turns out that we will need to vaccinate people every year, it’s going to be a real challenge,” he added. “A tablet vaccine like

Clene Nanomedicine is a clinical-stage biopharmaceutical company focused on treating neurodegenerative diseases. Its chief asset is CNM-Au8, a bioenergetic nanocatalyst under development as an add-on treatment for neurodegenerative diseases like Parkinson’s disease, multiple sclerosis, and Amyotrophic Lateral Sclerosis. CNM-Au8 is part of a new class of drugs called bioenergetic nanotherapeutics that harnesses the properties of

The drug in question, Cerevance, significantly improved cognitive impairments in patients suffering from schizophrenia. Dr Margolin discusses the structure of the drug trail, details the science behind the drug itself, and previews the next steps of his research.

Cue Biopharma has managed to persevere through the COVID pandemic by employing a variety of strategies. President and Chief Scientific Officer, Anish Suri, and Ken Pienta, acting Chief Medical Officer discuss their experiences.

Chiasma was trading 4% higher in the opening minutes on Wednesday.

Cambridge Science Park-based Cerevance has confirmed positive results from a trial of a potential treatment for cognitive impairment associated with schizophrenia.

Christopher J. Barnum, PhD, of INmune Bio, Inc discusses XPro1595, developed by INmune Bio, and how it may provide neuroprotective benefits for those at risk of developing Alzheimer disease.

Any time we have an opportunity to talk with Jeff Wolf, we take it – especially when the conversation tackles the highs and lows of leading a biotech startup. Currently the founder, chairman, and CEO at the clinical-stage immuno-oncology biopharma Heat Biologics (HTBX), Wolf previously founded or co-founded Avigen, Elusys, TyRx, Generation One, and Seed

Vaxart announced new data from its Hamster Challenge Study today, showing that its oral COVID-19 vaccine candidate can potentially reduce viral load and induce a significant immune response.

As marketability goes—and despite a growing unmet medical need—Lyme disease vaccine programs have suffered a futile fate. With its VLA15 candidate, French specialty vaccine company Valneva is trying to change that. 

Aiming to shed the legacy of an epic Alzheimer’s fail a few years ago, Axovant $AXGT is changing its name in a full corporate rebrand. The company announced Tuesday it will now be called Sio Gene Therapies as it completes what’s been a three-year pivot away from Alzheimer’s disease and toward, well, gene therapy.

Heat Biologics in Research Triangle Park is also working on a vaccine to combine with one like Pfizer’s to generate a more robust immune response.

Jewish Hospital has treated its first patient as part of a national study that hopes to prevent the progression of pulmonary complications due to COVID-19.

Though a COVID-19 vaccine could be released by year’s end or soon after, healthcare professionals say getting it to everyone who needs it is expected to take over a year.

Two genetic signatures that Rain Therapeutics scientists are focusing on are MDM2 gene amplification and wild-type p53 status, which tend to be exclusive events in malignancies.

South San Francisco-based Vaxart recently announced they had entered into a phase 1 trial for their VXA-CoV2-1 vaccine. Vaxart is a biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform.

Paula Ragan, Ph.D., is one of those leaders and one of a select group who not only was mentored by Termeer — an industry legend lost too soon — but cofounded a company with him. Today, she’s part of another elite group: female CEOs of biopharmaceutical companies. This is the story of how she went

Compugen Ltd. recently presented new research data further supporting the PVRIG protein coding gene as a potentially promising target for cancer immunotherapy. These data suggest that PVRIG inhibition may enhance T cell priming and infiltration into tumors and provide further evidence supporting the potential advantages of targeting PVRIG—alone and in combination with TIGIT and PD-1 inhibitors—in